[Phase II study of carboplatin in head and neck cancer].
To evaluate the clinical efficacy and safety of carboplatin for head and neck cancer, a phase II study was conducted in 21 institutions. Eighty-eight patients were entered into this trial, of which 70 were evaluable. Carboplatin was administered intravenously over 0.5-1 hr at the dose of 400 mg/m2 in good risk cases and 300 mg/m2 in poor risk cases. One patient achieved complete response(CR) and 13 achieved partial response(PR) with an overall response rate of 20%. In terms of response by histology, the response rate was 22% in cases of squamous cell carcinoma. The response rate was 26% in previously untreated patients and 16% in previously treated patients. One CR and 2 PR were achieved in 14 patients with prior cisplatin treatment. Toxicity was observed in 47% of the 70 evaluable patients. Nausea and vomiting were the most common toxicity observed (36%) followed by anorexia in 27%. Concerning hematologic toxicity, thrombocytopenia was noted in 32% and leukopenia in 29%. Elevation of BUN and creatinine was observed in only 2 cases and 1 case, respectively. It was concluded that carboplatin suggested activity similar to cisplatin, and also could be safely used at the outpatient level.
Inuyama
Y
Y
Dept. of Otorhinolaryngology, School of Medicine, Keio University.
Togawa
K
K
Morita
M
M
Takeoda
S
S
Kaneko
T
T
Takemiya
S
S
Ono
I
I
Nomura
Y
Y
Okuda
M
M
Kikuchi
K
K
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000855:Anorexia / Q000139:chemically induced; D016190:Carboplatin; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D004341:Drug Evaluation; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy*; D006801:Humans; D007262:Infusions, Intravenous; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012074:Remission Induction; D013921:Thrombocytopenia / Q000139:chemically induced; D014839:Vomiting / Q000139:chemically induced
D009944:Organoplatinum Compounds; D016190:Carboplatin